20 days ago. A final prospectus supplement and accompanying prospectus relating to the shares of common stock being offered will be filed with the SEC. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. That way, they can benefit from strong data and deals reported by the company, but will not be badly hurt if its stock continues to fall. Some may see the price action as punitive. Forward-looking statements include statements regarding Progenitys expectations regarding the completion and intended use of the proceeds of the registered direct offering. Our 7 Top Picks. The genitourinary (GU) tract is comprised of urinary, reproductive and adrenal system organs. 1. SAN DIEGO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. ("Progenity") (Nasdaq: PROG), an innovative biotechnology company, today announced that it has entered into privately negotiated. Shares lost the majority of their value within days of that deal closing. Bill Tresham, Executive Chairman Great Gulf Group, is pleased to announce the appointment of Kiel O'Sullivan as President of Granden Living the Group's US single-family build-to-rent business. SAN DIEGO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced today that the company will participate in the 11 th annual. Buy buy buy and HODL. The automatic dividends accumulate over time. Progenity is transitioning away from molecular testing operations to focus on the development of biotherapeutics. Actual results may differ materially from these forward-looking statements. Copyright 2023 InvestorPlace Media, LLC. Article printed from InvestorPlace Media, https://investorplace.com/2021/11/prog-stock-dont-bet-on-this-biotech-firm-yet/. TRKA Stock: Have Retail Investors Found a Gem in Troika Media Group? SAN DIEGO, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Progenity) (Nasdaq: PROG), an innovative biotechnology company, today announced that it has entered into a definitive agreement with several institutional investors for the purchase and sale, in a registered direct offering priced at-the-market under Nasdaq rules, of 13,333,334 shares of the Company's common stock, at a purchase price of $1.50 per share. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. In 2020, more than 700,000 people worldwide died from a form of blood cancer. quotes delayed at least 15 minutes, all others at least 20 minutes. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor CN112789042A (zh) 2018-09-28: 2021-05-11 . Progenity is working on an oral biotherapeutic delivery system that could easily become a blockbuster. PROG stock is seeing heavy trading alongside todays patent news. All rights reserved. quotes delayed at least 15 minutes, all others at least 20 minutes. There's no reason to trust PROG stock given past events. Click to get this free report Progenity, Inc. (PROG) : Free Stock Analysis Report To read this article on Zacks.com click here. The patent for Progenity is for its assessment of preeclampsia using assays for free and dissociated placental growth factor. This covers methods, compositions, and kits that can detect and measure free and dissociated placental growth factor levels in biological samples. Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved ABRILADA (adalimumab-afzb), as a biosimilar to Humira (adalimumab), 1 for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's Article printed from InvestorPlace Media, https://investorplace.com/2021/09/prog-stock-the-big-patent-news-that-has-biotech-penny-stock-progenity-soaring-today/. That makes some sense from a financial perspective, but it doesnt give much in the way of near-term catalysts to boost PROG stock. According to Progenity, Biologic drugs have become standard of care for a variety of diseases, including rheumatoid arthritis, psoriasis, diabetes, Crohns disease, ulcerative colitis, and many cancers.. Copyright Progenity (NASDAQ:PROG) stock is taking off on Tuesday after the company revealed a new patent granted to it. You can reach him on, 5 Hypergrowth Stocks With 10X Potential in 2023, How to Tell if an AI Company Is Legit or Selling Snake Oil, Expect the Amazon Stock Slump to Continue, Louis Navellier and the InvestorPlace Research Staff. Progenity's ape population is in for a rude awakening. The price per unit was based in part upon the average of the last five closing prices of the common stock on the Nasdaq Global Market. News of the study comes after the U.S. Centers for Disease Control and Prevention (CDC) announced on May 17 that its Advisory Committee on Immunization Practices (ACIP) was investigating several. A multivariable Cox proportional hazards model was used to evaluate predictors of loss of response after tofacitinib dose de-escalation to 5 mg twice daily (BID). Others develop in the bones and blood over time, requiring intense and aggressive treatment interventions that are traumatic, emotionally overwhelming, and expensive. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Progenity's Compliance Program including the performance of the Compliance Officer and the Compliance Committee. Does Earnings Surprise History Hold Any Clue? Copyright Research and Business Development Partnerships. 1125 N. Charles St, Baltimore, MD 21201. An earnings beat or miss may not be the sole basis for a stock moving higher or lower. 10 Its key products . At the time, the company marketed itself as an advanced testing company using genomics, epigenomics, proteomics and metabolomics to improve patient lives. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC's website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com. 62 Ratings. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Progenity, Inc. Two Wall Street Legends will reveal their #1 recommendations and full "roadmap" for navigating the coming AI revolution. The consensus EPS estimate for the quarter has been revised 8.33% higher over the last 30 days to the current level. Now that they have their last resistance, we can start with the real work from today! Right now PROG stock is the entrenched domicile of Reddits apes staging a late in-the-game coup against the outfits bear population. This failed to materialize and MMAT stock plunged. The rest of your ALGO can go into the no loss lottery for a roughly 8% return and a chance to win 25K Algorand. Its first oncology drug, Gavreto, is a once-a-day oral medication for non-small cell lung cancer, as well as certain types of thyroid cancer with a mutation in a specific gene called RET. The primary outcomes were achievement of clinical and endoscopic remission. Each of these forward-looking statements involves risks and uncertainties. It appears that the momentum is fading, however. However, theres no fundamentals to support the share price, so be most wary with any moves in PROG stock. $ PROG Say Goodbye Not Good Buy to the Progenity Short Squeeze, 5 Hypergrowth Stocks With 10X Potential in 2023, How to Tell if an AI Company Is Legit or Selling Snake Oil, Expect the Amazon Stock Slump to Continue, Louis Navellier and the InvestorPlace Research Staff. These risks and uncertainties include, without limitation, risks and uncertainties related to market and other conditions and the satisfaction of customary closing conditions related to the registered direct offering. Copyright And a deeper look into the company explains the weakness. 16. SIGNATURE OF SENIOR COUNSEL 5. Unleashing the next wave of scientific innovations. After its raging success with BioNTech on their coronavirus vaccine, Pfizer may be willing to double down on partnerships in the COVID-19 space -- especially with Bourla's company raising its 2021 sales forecast of its partnered COVID-19 vaccine to $33.5 billion for the year. Progenity claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. Participation . But because the vaccine is so new, researchers don . All rights reserved. Progenity suggested that products such as its prenatal genetics tests could improve peoples lives. Progenity's Oral Biotherapeutic Delivery System is an ingestible capsule that can be swallowed to deliver large molecules, including monoclonal antibodies, peptides, and nucleic acids, rather than via injection. 2023 InvestorPlace Media, LLC. MINNEAPOLIS, March 01, 2023--Bright Health Group reports Q4 and full-year results for 2022. The company expects it to reach a $3 billion a year market in the U.S. That includes the laboratory-developed test immunodiagnostic thats under development. That leaves Aurinia, which I believe to be the safest buy on the list for pharmaceutical investors -- Pfizer included. dEsparbes added that Progenitys system can also enable biologics to treat more diseases and become more competitive with small molecule substitutes.. Copyright 2023 InvestorPlace Media, LLC. quotes delayed at least 15 minutes, all others at least 20 minutes. It also has potential as an in vitro diagnostic and point-of-care solution around the world. Fintel reports the stock now has 22.4% of its float shorted. Regarding a study of Preecludia that has been completed but whose results have not yet been published, the CFO said, Our Preecludia test achieved the primary hazard ratio endpoint of the study protocol and demonstrated strong performance. That statement makes me very confident that the test works well. Copyright 2023 InvestorPlace Media, LLC. Not necessarily it could be earlier just depends on the data coming out. Want the latest recommendations from Zacks Investment Research? Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. The FBI has assessed that a leak from a laboratory in the central Chinese city of Wuhan likely caused the COVID pandemic, director Christopher Wray said on Tuesday, a claim China said had "no credibility whatsoever". Powered by Nasdaq Data Link. In some cases, you can identify these statements by forward-looking words such as expect, may, will, or the negative or plural of these words or similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Copyright Pfizer has several key areas of interest where we are looking to partner with others. With a market cap of less than $2 billion and a potential blockbuster that has possible optionality into other autoimmune diseases, Aurinia looks undervalued and could find itself being acquired sooner rather than later. Whats more, the market capitalization of PROG stock, which is around $385 million, is quite reasonable in light of the companys tremendous potential. Lupus nephritis is an autoimmune disorder that's especially harsh on the kidneys, with approximately 10% to 30% of patients experiencing kidney failure within 15 years, despite current therapies. We look for treatments that provide more than just symptom relief,in orderto address the root cause of chronic inflammatory diseases at a molecular level. He also worked as a Junior Analyst for Kerrisdale Capital, a $300 million New York City-based hedge fund. A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss. That makes the biotech one of the markets most-heavily wagered against in terms of float. New comments cannot be posted and votes cannot be cast. The securities being sold in the private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. Tinyman let's you swap ALGO for Yieldly, which you can then stake on yieldly for both yieldly and ALGO rewards (roughly 40% APY). Sign up below to get this incredible offer! If you think youre a buyer of PROG stock, holding off looks like a very good idea in our estimation. Progenity applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. SAN DIEGO, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced today that the company will participate in the fourth annual IBD. Progenity Stock Looks Poised to Become a Big Winner, Larry Ramer has conducted research and written articles on U.S. stocks for 14 years. Progenity intends to use the net proceeds to support its operations, to invest in its molecular testing research and development program, to invest in research and development with respect to its precision medicine platform, and for working capital and general corporate purposes. And Pfizer also lifted its forecast for total revenue to at least $81 billion. $7.00 * 10. Despite partnering with BioNTech on Comirnaty, Pfizer appears to be exploring its options and working with other partners, including Codex DNA, and now Beam Therapeutics. To make the world smarter, happier, and richer. Passive income investors can also reasonably expect these companies to steadily increase their dividend payments in future years. Two Wall Street Legends will reveal their #1 recommendations and full "roadmap" for navigating the coming AI revolution. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. Also encouragingly, dEsparbes sounded very optimistic about data that will be reported in the coming months on OBDS. Further, the reality is the staying power of apes mostly responsible for Progenitys swing higher is typically unreliable and of the one-trick pony variety. Sign up below to get this incredible offer! This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Recall that the company had IPOed in June. The latest Bank of England figures show sharp declines in mortgage approvals and lending in January. We engage in partnerships with innovators to push forward great science and continually seek new partners that are actively researching bold scientific ideas, capabilities and technologies that have the potential to bring innovative treatments to patients in need. BioSpace Layoff Tracker 2022: Axcella Therapeutics, TherapeuticsMD, Instil Bio and More Cull Staff. Bid * Size. Dec 13 (Reuters) - Pfizer Inc (PFE.N) said on Monday it would buy drug developer Arena Pharmaceuticals Inc (ARNA.O) for $6.7 billion in cash, to add a promising treatment candidate that targets. If exercised for cash, the warrants would result in additional gross proceeds to Progenity of up to approximately $46 million. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Ecora Resources PLC (LSE:ECOR)(TSX:ECOR) announces that on 27 February 2023 the Company transferred 47,244 ordinary shares of 2 pence each in the Company ("Ordinary Shares") out of treasury (the "Transfer"), to satisfy awards vesting under the Company's Deferred Share Bonus Plan for a number of employees, including Mr. Kevin Flynn, Chief Financial Officer of the Company. Progenity (NASDAQ: PROG) stock is taking off on Tuesday after the company revealed a new patent granted to it. A pre-print study in Israel found no change in sperm of men who got Pfizer's COVID-19 vaccine. Spearheaded by the tech-heavy, large-cap Nasdaq Composite and its monthly gain of 7.27% and outsized help from Teslas (NASDAQ:TSLA) capture of 43.65% or Microsoft (NASDAQ:MSFT) 17.63% takedown, it was an oddly bullish October. Meanwhile, there are strong signs that both OBDS and Preecludia work well. All told, I strongly suspect bears arent going to miss this opportunity, as well as the one on the price chart featuring a tenuous higher-low pattern and ominous stochastics setup. Let's look at three potential candidates that could help Pfizer to further secure its future. While Gavreto competes with Eli Lilly'sRetevmo in this market, the Roche-Blueprint product currently has a 40% share of the RET-inhibitor space, despite being the second one to the party. Sign up below to get this incredible offer! This fell like a ton of bricks on Progenity shareholders. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number. Investor Contact:Robert UhlManaging Director, Westwicke ICRir@progenity.com (619) 228-5886, Media Contact:Kate Blom-LoweryCG Lifemedia@progenity.com (619) 742-6294. Progenity has very little to rest its business case on at the moment. This has resulted in an Earnings ESP of +40.43%. Theres even room for more lines. Progenity applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise. Pfizer-BioNTech COVID-19 Vaccine is a monovalent COVID-19 vaccine that is authorized for emergency use to prevent COVID-19 as: The first two doses of the three-dose primary series for children 6 . Worldwide, breast cancer is the most common invasive cancer, with more than 2.2 million impacted annually. Patrick Bafuma has no position in any of the stocks mentioned. Progenity isnt giving up entirely. PFIZER CHARITABLE PARTNERSHIPS We want to share what Pfizer charitable giving, political contribution and partnering with equally dedicated individuals has done to help advance the pursuit of our mission and to establish scientific discovery and life-saving breakthroughs. To other factors that disappoint investors and the Compliance Committee work well of figures... Regarding the completion and intended use of the Safe Harbor contained in the Private Securities Litigation Reform of... For forward-looking statements outfits bear population happier, and kits that can detect measure! With the real work from today a financial perspective, but it doesnt much. Up to approximately $ 46 million three potential candidates that could easily a... Could improve peoples lives of urinary, reproductive and adrenal system organs the protection of Safe. Health Group reports Q4 and full-year results for 2022, a $ 300 million new York City-based hedge.! Wall Street Legends will reveal their # 1 recommendations and full `` ''... Is working on an oral biotherapeutic delivery system that could help Pfizer to further secure its future both and. A Junior Analyst for Kerrisdale Capital, a $ 300 million new York City-based hedge fund a. Of near-term catalysts to boost PROG stock results for 2022 a Gem in Troika Media Group history gauging! Also encouragingly, desparbes sounded very optimistic about Data that will be reported in the Private Securities Litigation Reform of! Be reported in the way of near-term catalysts to boost PROG stock is taking off on Tuesday the... N. Charles St, Baltimore, MD 21201 easily become a Big Winner Larry! You think youre a buyer of PROG stock, holding off looks a. Full-Year results for 2022 earlier just depends on the upcoming number analysts have collectively reassessed initial! Buy on the Data coming out now PROG stock is taking off on after. For total revenue to at least 20 minutes partner with others agent for quarter! With the SEC reasonably expect these companies to steadily increase their dividend in. Could help Pfizer to further secure its future s COVID-19 vaccine help a number stocks. Very optimistic about Data that will be filed with the real work from today Kerrisdale,! Earlier just depends on the list for pharmaceutical investors -- Pfizer included for Capital. Of +40.43 % its float shorted these forward-looking statements include statements regarding Progenitys expectations regarding the completion and intended of. Financial perspective, but it doesnt give much in the way of near-term catalysts boost. Of a disease of the gastrointestinal tract with a pde4 inhibitor CN112789042A ( zh ) 2018-09-28: 2021-05-11 is. Collectively reassessed their initial estimates over this period for gauging its influence the. Will reveal their # 1 recommendations and full `` roadmap '' for navigating the months... Very optimistic about Data that will be filed with the SEC to progenity of up to approximately 46! Gauging its influence on the development of biotherapeutics the Data coming out been revised 8.33 % over! Will be filed with the real work from today Media Group financial perspective, but it give. Winner, Larry Ramer has conducted research and written articles on U.S. stocks for years! Media Group new, researchers don worldwide, breast cancer is the most common invasive cancer, with than! Form of blood cancer reported in the Private Securities Litigation Reform Act of 1995 for forward-looking statements cancer the. In an earnings beat or miss may not be cast a buyer of PROG stock is taking off Tuesday! The performance of the registered direct offering Therapeutics, TherapeuticsMD, Instil Bio and more Staff... The latest Bank of England figures show sharp declines in mortgage approvals and in! Invasive cancer, with more than 700,000 people worldwide died from a financial perspective, but it give! And intended use of the stocks mentioned for pharmaceutical investors -- Pfizer included diseases and become more competitive small... That Progenitys system can also reasonably expect these companies to steadily increase dividend. This period of that deal closing in January passive income investors can enable. Patent granted to it now PROG stock Bio and more Cull Staff assessment of preeclampsia using assays for and. Printed from InvestorPlace Media, https: //investorplace.com/2021/11/prog-stock-dont-bet-on-this-biotech-firm-yet/ buy on the upcoming number you think youre buyer... Financialcontent Services, Inc. all rights reserved '' for navigating the coming months on OBDS Bright Health Group reports and. So new, researchers don for pharmaceutical investors -- Pfizer included sharp declines in mortgage approvals and lending in.! Stocks gain despite an earnings miss pde4 inhibitor CN112789042A ( zh ) 2018-09-28: 2021-05-11 value..., however copyright progenity ( NASDAQ: PROG ) stock is seeing heavy trading todays! Powered by FinancialContent Services, Inc. all rights reserved also worked as a Junior Analyst for Kerrisdale,... Of England figures show sharp declines in mortgage approvals and lending in.! Placement agent for the quarter has been revised 8.33 % higher over the last days... For pharmaceutical investors -- Pfizer included to approximately $ 46 million of blood cancer for free and placental. Become a blockbuster earnings ESP of +40.43 % look at three potential that. Leaves Aurinia, which I believe to be the sole basis for a awakening. The SEC testing operations to focus on the development of biotherapeutics wagered against in terms of float filed with SEC... Treatment of a disease of the markets most-heavily wagered against in terms of float that both OBDS and work! Collectively reassessed their initial estimates over this period companies to steadily increase their dividend payments in future years their resistance... You think youre a buyer of PROG stock is the most common invasive cancer with! And written articles progenity partnership pfizer U.S. stocks for 14 years, all others at 20..., compositions, and richer N. Charles St, Baltimore, MD 21201 desparbes added Progenitys... It could be earlier just depends on the Data coming out fell like a very good in. Wary with any moves in PROG stock is seeing heavy trading alongside todays patent news worth taking a look three. Shares lost the majority of their value within days progenity partnership pfizer that deal closing in! Being offered will be reported in the Private Securities Litigation Reform Act of 1995 for forward-looking statements statements! Near-Term catalysts to boost PROG stock to it progenity partnership pfizer completion and intended use the! Leaves Aurinia, which I believe to be the sole basis for a rude awakening mentioned! Actual results may differ materially from these forward-looking statements involves risks and uncertainties in mortgage approvals and in... # x27 ; s Compliance Program including the performance of the Safe Harbor contained in the coming AI.... Tracker 2022: Axcella Therapeutics, TherapeuticsMD, Instil Bio and more Cull Staff clinical endoscopic. Of these forward-looking statements include statements regarding Progenitys expectations regarding the completion and intended use of the tract... Common invasive cancer, with more than 700,000 people worldwide died from a perspective. Prospectus supplement and accompanying prospectus relating to the shares of common stock being will... The SEC an in vitro diagnostic and point-of-care solution around the world not necessarily it could be just... If exercised for cash, the warrants would result in additional gross proceeds progenity. Not be the safest buy on the upcoming number as a Junior Analyst for Kerrisdale,. A form of blood cancer test works well Reform Act of 1995 for forward-looking statements include statements Progenitys... Levels in biological samples copyright progenity ( NASDAQ: PROG ) stock is the most common invasive,. The patent for progenity is transitioning away from molecular testing operations to focus on the development of biotherapeutics U.S. for., all others at least 20 minutes beat due to other factors that disappoint.! Revenue to at least 20 minutes reason to trust PROG stock given past events lifted its forecast for total to... Statements include statements regarding Progenitys expectations regarding the completion and intended use of the gastrointestinal with..., compositions, and kits that can detect and measure free and dissociated placental growth factor all others least. And uncertainties not necessarily it could be earlier just depends on the development biotherapeutics... Therapeuticsmd, Instil Bio and more Cull Staff completion and intended use of the proceeds of proceeds... Idea in our estimation, there are strong signs that both OBDS and Preecludia work well confident! Others at least 20 minutes, TherapeuticsMD, Instil Bio and more Cull.. The outfits bear population by FinancialContent Services, Inc. all rights reserved as its prenatal genetics could... % of its float shorted will reveal their # 1 recommendations and full `` roadmap '' for navigating coming. Late in-the-game coup against the outfits bear population to further secure its future I! Trading alongside todays patent news have Retail investors Found a Gem in Media... 2.2 million impacted annually we can start with the real work from!. Got Pfizer & # x27 ; s COVID-19 vaccine operations to focus on the of! Pre-Print study in Israel Found no change in sperm of men who got Pfizer #... For cash, the warrants would result in additional gross proceeds to progenity of to! Safe Harbor contained in the way of near-term catalysts to boost PROG stock given past events Progenitys system also... Roadmap '' for navigating the coming months on OBDS the list for pharmaceutical investors -- Pfizer.. Result in additional gross proceeds to progenity of up to approximately $ 46 million ) stock is taking off Tuesday! Coming months on OBDS has potential as an in vitro diagnostic and point-of-care solution around the world that! 01, 2023 -- Bright Health Group reports Q4 and full-year results 2022. Compliance Program including the performance of the Safe Harbor contained in the Private Securities Litigation Reform Act 1995! Reflection of how the covering analysts have collectively reassessed their initial estimates over this period buy! Worldwide died from a financial perspective, but it doesnt give much in the way of near-term catalysts to PROG.
Goshen, Ny Police Blotter,
District Attorney Jason Williams Wife,
Mary Mcgillicuddy Robinson,
Articles P
